Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $8
Perspective Therapeutics, Inc. CATX
$0.79
βΌ -7.28%
($-0.06)
📉 Near 52W Low
Open
$0.87
Prev Close
$0.86
Day Range
$0.79 β $0.91
52W Range
$0.78 β $6.16
Market Cap
$97.67M
Beta
2.05
EPS (TTM)
$-1.33
π Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2002-05-31 |
| Shares Out. | 114,150,000 |
| Website | perspectivetherapeutics.com/ β |
| Phone | 18009279800 |
| Employees | 166 |
| Revenue | $81,000 |
| Gross Profit | $81,000 |
| Net Income | -$26.8M |
| Free Cash Flow | -$121.3M |
| Total Assets | $392.0M |
| Total Liabilities | $68.2M |
| Equity | $323.9M |
About Perspective Therapeutics, Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Perspective Therapeutics, Inc. is a publicly traded company under the ticker symbol CATX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
21 analysts (2026-11-01)
π° Latest News for CATX
Perspective Therapeutics: Q3 Earnings Snapshot
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026
Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-Ξ±-NET) in Advanced SSTR2 Expressing NETs
Perspective Therapeutics (CATX) Stock Sees Fair Value Moves Lower As Analysts Weigh Lead 212 Risks